# Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

> **NCT02382406** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nisha Mohindra, MD** · enrollment: 46 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** MK-3475 (Phase I)
- **DRUG:** MK-3475 (Phase II)

## Key facts

- **NCT ID:** NCT02382406
- **Lead sponsor:** Nisha Mohindra, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-04
- **Primary completion:** 2022-04-14
- **Final completion:** 2022-04-14
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** The study was completed. It was fully accrued.
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382406, "Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02382406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*